Special Report: Amid a strong run of positive news flow, DMX shares have climbed more than 500 per cent since the start of April.

Biotech company Dimerix (ASX:DMX) has won federal government funding to clinically evaluate the effectiveness of its proprietary DMX-200 treatment against symptoms of COVID-19.

The $1m grant will support the company’s inclusion in the REMAP-CAP study – a global initiative to test treatments for “Acute Respiratory Distress Syndrome associated with COVID-19”, the company said.

 

Cross-over opportunity

In addition to the COVID-19 opportunity, DMX-200 has the potential to be the first ever treatment for FSGS (focal segmental glomerulosclerosis) – an advanced kidney disease that affects both adults and children as young as 2 years old.

Shares in the company surged in late-June after a phase-two trial met the required endpoints around both safety and efficacy.

The drug has orphan status in both the US and Europe for FSGS, which allows for fast-tracked regulatory approval and opens the company up to a multi-billion-dollar market opportunity.

But importantly, a key aspect of the drug’s use-case is targeted towards “reducing damage from inflammatory immune cells, by blocking their signalling and limiting subsequent movement”, Dimerix said.

Patients suffering from acute symptoms of COVID-19 often face severe lung incapacitation, which is a direct by-product of their body’s immune response.

“Global experts see DMX-200 as a compelling treatment option to limit inflammation in the lungs during infection of the SARS-CoV2 virus,” Dimerix said.

 

Global effort

REMAP-CAP is an international study endorsed by the World Health Organisation, to help fast-track evidence-based treatments as part of the global fight against coronavirus.

The study is coordinated by the Australian and New Zealand Intensive Care Research Centre, as part of a global collaborative effort comprising 30 partner organisations and 240 sites across 16 countries, with more than 7,000 patients enrolled.

Monash University professor Steve Webb, chair of the REMAP-CAP International Trial Steering Committee, said he was pleased to support the ongoing development of the DMX-200 treatment.

“By utilising an adaptive design rather than using a traditional trial approach, we are more likely to get to answers faster, while keeping our patients as safe as possible,” Webb said.

“REMAP-CAP is an optimal study to identify potential treatments for COVID-19 as safely, quickly, and effectively as possible.”

Along with the COVID-19 study, Dimerix is staying busy with plenty of irons in the fire – as would be expected for one of the most exciting biotech success stories on the ASX.

The company is currently awaiting Phase-2 study results for its diabetic kidney disease treatment, which have an expected data read-out in the first few weeks of September.

In addition, it’s now undertaking planning towards a global phase-three program for its market-leading FSGS treatment, as it targets a global sales opportunity which just in the US alone could be worth more than $US6bn ($8.2bn).

This article was developed in collaboration with Dimerix, a Stockhead advertiser at the time of publishing.

 This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Read MoreHealth

Featured Companies

You might be interested in